News | January 11, 2016

AiCure’s Artificial Intelligence Platform Draws $12.25 Million Series A (New York, NY) – January 11, 2016 – AiCure, an artificial intelligence company connecting the world’s patients to better treatments and improved health, has closed a Series...

News | January 7, 2016

Principia Biopharm advances BTK inhibitor program in autoimmune disease and FGFR inhibitor program in oncology Initiates Phase 2 clinical trial of BTK inhibitor PRN1008 in orphan autoimmune disease Advances Phase 1 clinical trial of FGFR1-4 inhibitor PRN1371 in solid...

News | January 7, 2016

Dimension Therapeutics Announces Initiation of Phase 1/2 Study for DTX101 for the Treatment of Hemophilia B Receives Positive Opinion on European Orphan Drug Designation CAMBRIDGE, Mass., Jan. 07, 2016 (GLOBE NEWSWIRE) — Dimension Therapeutics, Inc....

News | January 6, 2016

Dimension Therapeutics Announces Orphan Drug Designation of DTX301 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency CAMBRIDGE, Mass., Jan. 06, 2016 (GLOBE NEWSWIRE) — Dimension Therapeutics, Inc. (NASDAQ:DMTX), a leading gene therapy company...

News | December 16, 2015

Versartis’ VRS-317 6-Month Data Published in The Journal of Clinical Endocrinology & Metabolism Results Show Positive Safety and Efficacy Data With Similar Outcomes Across Three Dosing Regimens MENLO PARK, Calif., Dec. 16, 2015 (GLOBE NEWSWIRE) —...
neque. adipiscing pulvinar consectetur dictum Aenean